MAPK9

Across TCGA pan-cancer cohorts, MAPK9 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MAPK9’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MAPK9 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MAPK9 is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where MAPK9 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAPK9 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.268	<.001	11	view →
COAD	Male	III,IV	−0.262	<.001	11	view →
LSCC	Female	II,III,IV	−0.541	<.001	9	view →
LUAD	Male	III,IV	−0.347	<.001	9	view →
HNSC	Male	All	−0.175	<.001	6	view →
PDAC	All	All	−0.168	.013	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MAPK9–CCRCC

Open the CCRCC breakdown →